Introduction
Organometallic complexes offer enormous scope for the design of anticancer candidates due to their versatile structures, potential redox features and wide range of ligand substitution rates.
1 For examples, titanocenyl, ferrocenyl and Ru II arene
anticancer complexes are attracting current attention. 2 However, there are only a limited number of reported studies on the anticancer activity of organometallic iridium complexes. 3 In general iridium(III) complexes are usually thought to be relatively inert. We report studies of the aqueous chemistry (hydrolysis, acidity of the resultant aqua adducts), nucleobase binding and cancer cell toxicity of Ir III complexes containing C,N-chelating ligands based on 2-phenylpyridine with electron-donating or electron-withdrawing substituents, and with Cp* and substituted Cp* ligands, Chart 1.
The results suggest that this new class of organometalic Ir(III) complexes is well suited for development as anticancer agents. 
Chart 1. Iridium Cyclopentadienyl Complexes Studied in This Work

Experimental Section
Materials. 2-Phenylpyridine, 2-(2,4-difluorophenyl)pyridine, 2-(p-tolyl)pyridine, 2-phenylquinoline, 9-ethylguanine, and 9-methyladenine were purchased from Sigma-Aldrich. Methanol was distilled over magnesium/iodine prior to use. Dimers Hz), 7.31 (d, 1H, J = 8.8 Hz), 7.10 (t, 1H, J = 6. 3 Hz), 6 .49 (t, 1H, J = 9.5 Hz), 1.67 (s, 15H). 13 C NMR (CDCl 3 ): δ = 151. 54, 143.53, 137.52, 122.7, 117.28, 98.20. 89.02, 77.35, 8.78 53, 137.13, 135.65, 131.14, 128.77, 127.33, 123.90, 122.20, 118.96, 77.35, 9. 45, 139.90, 136.98, 135.57, 131.05, 129.01, 127.22, 123.93, 122.51, 118.94, 77.34, 9.88 
Methods and Instrumentation.
X-ray crystallography. All diffraction data were obtained on an Oxford
Diffraction Gemini four-circle system with a Ruby CCD area detector using Mo Kα radiation. Absorption corrections were applied using ABSPACK. 7 The crystals were mounted in oil and held at 100(2) K with the Oxford Cryosystem Cobra. The structures were solved by direct methods using SHELXS (TREF) 8 derivatives, and the C,N-chelating ligands are 2-(p-tolyl)pyridine (tpy, 1), Table 1 , and selected bond lengths and angles are listed in Table 2 . Complexes 2 and 5 adopt the expected half-sandwich pseudo-octahedral "three-leg piano-stool" geometry with the iridium bound to a η 5 -cyclopentadienyl ligand (Ir to ring centroid distances of 1.829 and 1.825 Å, respectively). The Ir−Cl bond distances are 2.3989 (16) and 2.3886 (8) also formed 9-EtG adducts to the extent of 100% after 24 h. Only complex 2 containing 2-phenylquinoline showed less strong binding to 9-EtG (45%, Figure 4 and Table S1 ).
Complexes 3−5 formed moderately strong 9-MeA adducts (35−63% at equilibrium after 24 h, Table S1 ). Only complex 1 [(η 5 -C 5 Me 5 )Ir(tpy)Cl] showed an exceptionally high affinity for 9-MeA, with 90% adduct formation after 24 h. Complex 2 containing 2-phenylquinoline formed almost no 9-MeA adduct (<5%). Except for 2, two adenine nucleobase adducts were formed in the reactions between complexes 1, 3−5 with 9-MeA, most likely through iridium binding to N1 or N7 of adenine in a ratio typically of 1:5.
Competition reactions between equi-molar amounts of 9-EtG and 9-MeA and complexes 1, and 3−5 (ca. 1 mM) in 20% MeOD-d 4 /80% D 2 O (v/v, pH* ca. 7.4) at 310 K were investigated. In the competitive experiment, 9-EtG adducts 3G, 4G or 5G
were observed as the only product for complexes 3−5, and as 80% 9-EtG adduct for complex 1 (20% 9-MeA adduct), Table S1 . The 1 H NMR spectra for the competition reaction for 3 are shown in Figure 5 . Cytotoxicity. The cytotoxicity of complexes 1−5 towards A2780 human ovarian cancer cells was investigated, Figure S4 . Hydrolysis and pK a of Aqua Adducts. Since M-OH 2 (M = metal) aqua complexes are often more reactive than the equivalent chlorido complexes, 3a,12,15 hydrolysis of the M-Cl bonds can represent an activation step for transition metal anticancer complexes. 16 There are only a few previous studies of the aquation At chloride concentrations typical of blood plasma (104 mM) and cell cytoplasm (23 mM), complexes 1−5 were found to be almost all present in solution as the relatively unreactive chlorido species, and only about 5% of complexes 1−5 was present as the reactive aqua species at a chloride concentration of 4 mM close to that of the cell nucleus. These data suggest that aquation is suppressed almost totally at the saline concentration in blood. However, complexes 1−5 might be activated by aquation in the cell nucleus. Another possibility is that the complexes might react by direct substitution of chloride by nucleobases (DNA). analogues bearing the N,N-bound 2,2'-bipyridine (bpy) ligand. 3a Therefore, the replacement of the neutral bpy ligand by the anionic phpy ligand plays a significant role in decreasing the acidity of the aqua complexes, consistent with previous reports. 3a,19a The high pK a values of 1A−5A thus ensure that most of the hydrolyzed complexes would be present in the active aqua form at physiological pH.
The pH titration also showed that additional species were formed for all complexes studied here above pH 8.7 (Figure 3 Interactions with Nucleobases. Interaction with DNA is often associated with the cytotoxicity of metal anticancer drugs. 13 In this study, the interactions with model nucloebases, 9-EtG and 9-MeA, and with complexes 1−5 were investigated ( Figure 4 and Table S1 ). All the C,N-chelated Ir III complexes, except 2, showed an exceptionally high nucleobase affinity with 100% guanine adduct formation for 9-EtG, which may contribute to their high cytotoxicity. Complexes Complexes 1−5 bind more weakly to adenine compared to guanine. The competition between 9-EtG and 9-MeA for the C,N-bound Ir III complexes give rise to 9-EtG adducts as the only product for 3−5 and as major product for 1 (Figure 4 and Table S1 ), confirming that binding to guanine is stronger than to adenine. This may due to the steric hindrance caused by the NH 2 group at the 6-position of the adenine ring. In addition, guanine is usually considered to be a stronger electron donor than adenine. 21 The widely used anticancer drug in clinical, cisplatin, also prefers guanine over adenine. 22 3a,19a,20b,23 Ir III cyclopentadienyl complexes containing a neutral N,N-chelating ligand (phen, bpy, or ethylenediamine) bind selectively to 9-EtG, but not to adenine. 3a The formation of adenine adducts in this work may be due to the interaction between NH 2 of 9-MeA and negatively-charged carbons on the C,N-chelating ligand. Table 4 and Figure S4 . The activity of Ru II arene complexes also increases with the size of the coordinated arene. 25 This suggests that these phenyl groups may play a crucial role in the mechanism of action of these phenylpyridine complexes. First, the phenyl or biphenyl ring increases the hydrophobicity of the molecule, which may assist with passage across cell membranes. In addition, the extended phenyl rings can intercalate into DNA, thus causing distortion of DNA structure. We have reported that the intercalative ability of 1,10-phenanthroline Ir III chlorido complexes increases in the order of Cp xbiph > Cp xph > Cp*. 3a Complexes 4 and 5 containing phenyl or biphenyl substitutions may interact with DNA by a dual mode: nucleobase binding to iridium accompanied by intercalation of the phenyl groups, which is a different mechanism of action from that of cisplatin. 
Conclusions
